Correlation Between Neurocrine Biosciences and Eton Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Neurocrine Biosciences and Eton Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurocrine Biosciences and Eton Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neurocrine Biosciences and Eton Pharmaceuticals, you can compare the effects of market volatilities on Neurocrine Biosciences and Eton Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurocrine Biosciences with a short position of Eton Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurocrine Biosciences and Eton Pharmaceuticals.

Diversification Opportunities for Neurocrine Biosciences and Eton Pharmaceuticals

0.13

Correlation Coefficient

Neurocrine Biosciences  Eton Pharmaceuticals

Average diversification

The 3 months correlation between Neurocrine and Eton is 0.13. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and Eton Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eton Pharmaceuticals and Neurocrine Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurocrine Biosciences are associated (or correlated) with Eton Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eton Pharmaceuticals has no effect on the direction of Neurocrine Biosciences i.e., Neurocrine Biosciences and Eton Pharmaceuticals go up and down completely randomly.

Pair Corralation between Neurocrine Biosciences and Eton Pharmaceuticals

Given the investment horizon of 90 days Neurocrine Biosciences is expected to under-perform the Eton Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Neurocrine Biosciences is 1.7 times less risky than Eton Pharmaceuticals. The stock trades about -0.1 of its potential returns per unit of risk. The Eton Pharmaceuticals is currently generating about 0.02 of returns per unit of risk over similar time horizon. If you would invest  1,303  in Eton Pharmaceuticals on December 29, 2024 and sell it today you would lose (1.00) from holding Eton Pharmaceuticals or give up 0.08% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Insignificant
Accuracy	100.0%
Values	Daily Returns

Neurocrine Biosciences  vs.  Eton Pharmaceuticals

Neurocrine Biosciences

Risk-Adjusted Performance

Very Weak

Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

Eton Pharmaceuticals

Risk-Adjusted Performance

Weak

Compared to the overall equity markets, risk-adjusted returns on investments in Eton Pharmaceuticals are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of very weak basic indicators, Eton Pharmaceuticals may actually be approaching a critical reversion point that can send shares even higher in April 2025.

Pair Trading with Neurocrine Biosciences and Eton Pharmaceuticals

The main advantage of trading using opposite Neurocrine Biosciences and Eton Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurocrine Biosciences position performs unexpectedly, Eton Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eton Pharmaceuticals will offset losses from the drop in Eton Pharmaceuticals' long position.

The idea behind Neurocrine Biosciences and Eton Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.